News
We send the latest information from SMC Laboratories.
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…
Cholangiocarcinoma and Primary sclerosing cholangitis
On February 15, World Cholangiocarcinoma Day! Today we would like to introduce cholangiocarcinoma (CCA,…
Press Release Regarding STAM-HCC/IO+ Mice has been distributed.
We are pleased to announce that our STAM(TM)-HCC/IO+ mouse was introduced in PR Newswire (Kyodo News JBN). For…
Announcement of webinar 【MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1】
Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…
World COPD Day 2023 | “Breathing is Life – Act Earlier”
November 15th is World COPD Day, so why not learn more about COPD？ What is World COPD Day? World COPD D…
Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Mon…
Exciting News from 89bio, Inc.! U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in NASH
The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new dru…
Announcement of webinar 【New NAFLD nomenclature ~Redefining the NAFLD/NASH mouse model~】
Today, we are excited to invite you to join our Webinar that will be taking place on August 18th from 9:30 AM …
Redefinition from NAFLD/NASH to MASLD/MASH
The American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the…